Replies to post #24415 on RespireRx Pharmaceuticals Inc (RSPI)

[K-G]

GFP,
I still disagree with you on the difficulty of conducting a PIII RD trial. I think you are just considering the difficulty in gaining statistical significance in rescue usage for severe RD. It seems to me that establishing effectivity in preventative usage is pretty straight forward, and at worst just involves a larger sample size. The crash carts would still have Narcan. I would expect the ampakine usage in RD Rescue to be incremental, and occur after approval for preventative usage. But, if you never have a patient in a depressed respiratory state when they are preventatively treated, then you would significantly reduce your rescue market anyway.